Ulcerative Colitis Research Studies

Contact Information
University of Wisconsin GI and Hepatology Clinical Research Office:
(608) 263-4185
Learn more about clinical trials at www.clinicaltrials.gov
  • Severe, active ulcerative colitis
  • No need for immediate surgery
  • No other ulcerative colitis meds allowed, other than glucocorticoids or 5 ASAs
PET With Asacol (Ulcerative Colitis)
Principal Investigator (PI): Mark Reichelderfer, MD
Enrollment Target: 10 patients plus 5 controls
Use PET scanning to evaluate patients with active ulcerative colitis vs. patients with ulcerative colitis in remission. In addition, to assess and characterize the response to Asacol.
  • Any corticosteroids within one month prior to the baseline visit (including Budesonide)
  • Immunomodulatory therapy including, but not limited to, 6-mercaptopurine, azathioprine, cyclosporine or methotrexate within 3 months prior to the baseline visit
  • Received a dose of mesalamine-containing compound by any route from which more than 1.6 g/day of mesalamine was available within one week prior to the screening visit (NOTE: 4 g/day of sulfasalazine and 4.5 g/day of balsalazide are equivalent to 1.6 g/day of mesalamine); washout would be one week
  • Received any experimental or investigational drug for the treatment of ulcerative colitis during the one-month period prior to the baseline visit
Contact Information

If you are a patient interested in learning more about our clinical studies, or if you are a referring physician and believe one of your patients may be appropriate for one of these trials, please call the University of Wisconsin GI and Hepatology Clinical Research Office at (608) 263-4185.